US equities
|
MU
$983.62
▼-4.41%
SNDK
$1,470.27
▼-7.05%
NVDA
$225.38
▼-1.70%
SPCX
$163.94
▲+0.85%
META
$745.01
▲+3.66%
AMD
$589.29
▼-3.09%
AAPL
$341.54
▲+1.46%
INTC
$101.17
▼-3.38%
MU
$983.62
▼-4.41%
SNDK
$1,470.27
▼-7.05%
NVDA
$225.38
▼-1.70%
SPCX
$163.94
▲+0.85%
META
$745.01
▲+3.66%
AMD
$589.29
▼-3.09%
AAPL
$341.54
▲+1.46%
INTC
$101.17
▼-3.38%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Praxis Precision Medicines, Inc. - Common Stock
(NQ:
PRAX
)
253.00
-6.86 (-2.64%)
Delayed Quote
Updated: 10:28 AM EDT, Oct 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Praxis Precision Medicines, Inc. - Common Stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity
↗
July 10, 2025
Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal.
Via
Investor's Business Daily
Topics
Intellectual Property
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2025
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 04, 2025
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Assessing Praxis Precision Medicine: Insights From 5 Financial Analysts
↗
March 03, 2025
Via
Benzinga
The Analyst Verdict: Praxis Precision Medicine In The Eyes Of 4 Experts
↗
February 11, 2025
Via
Benzinga
Praxis Precision Medicines to Participate in Upcoming Conferences
May 20, 2025
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside
↗
May 07, 2025
Chardan initiates Praxis with a Buy rating, highlighting its epilepsy pipeline, strong cash position, and billion-dollar potential of vormatrigine.
Via
Benzinga
This Waste Connections Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
↗
May 07, 2025
Via
Benzinga
Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event
May 05, 2025
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Expert Outlook: Praxis Precision Medicine Through The Eyes Of 5 Analysts
↗
January 21, 2025
Via
Benzinga
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2025
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results
May 02, 2025
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Assessing Praxis Precision Medicine: Insights From 8 Financial Analysts
↗
May 01, 2025
Via
Benzinga
Deep Dive Into Praxis Precision Medicine Stock: Analyst Perspectives (8 Ratings)
↗
April 08, 2025
Via
Benzinga
Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies
April 08, 2025
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Participate in Upcoming April Conferences
April 03, 2025
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2025
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting
March 24, 2025
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 04, 2025
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Participate in Five Upcoming Investor Conferences
March 04, 2025
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Analysts Cut Price Targets For Praxis Precision After Trial Setback For Essential Tremor Candidate
↗
March 03, 2025
Praxis Precision Medicines' ulixacaltamide study for essential tremor faces setback as IDMC recommends stopping for futility. Topline results expected in Q3 2025.
Via
Benzinga
Keep an eye on the top gainers and losers in Friday's session.
↗
February 28, 2025
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.
Via
Chartmill
Friday's session: top gainers and losers
↗
February 28, 2025
Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via
Chartmill
These stocks are gapping in today's session
↗
February 28, 2025
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday.
Via
Chartmill
Praxis Precision Medicines Provides Update on Essential3 and Corporate Update
February 28, 2025
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 04, 2025
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Present at Two February Investor Conferences
February 03, 2025
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
↗
January 14, 2025
Via
Benzinga
Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities
January 12, 2025
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Present at J.P. Morgan Healthcare Conference
January 06, 2025
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
